Cosmo’s dermatology spin-out Cassiopea IPOes before the end of its Phase III

11/06/2015 - 2 minutes

Cassiopea, Cosmo Pharmaceutical’s spin-out, will be listed on the Swiss Stock Exchange. Cosmo Pharmaceutical plans to reduce its current 97% shareholding to below the 50% bar. The majority shareholder will give away the control of its subsidiary in order to have enough cash after the end of its Phase III ACNE-treatment, currently running in the US and Europe. 

Cosmo plans to offer around a 62% of the newly available shares to novel investors, while the remaining third of the shares will be offered in a preferred option for Cosmo’ shareholders. Dietmar Hopp’s dievini fund, Heinrich Herz and some of Cosmo’s senior managers already expressed their interest in Cassiopeia, attracted by its strong dermatology pipeline.

In fact, the dermatology field is a market where little innovation takes place despite the many existing opportunities. In the last 15 years, there have been no NCEs (new chemical entities) in acne on the US market, a fact that contrasts with the prevalence of the disorder. In the States, 17 million people have acne and 85% of the population between the ages of 12 and 24 get acne…

This content is available exclusively to our paying members.

Our members receive the following benefits:

  • Unlock premium articles
  • Download our industry reports
  • Remove all banner ads
  • Access 1,500+ archived posts
  • Support our independent media
Already a member? Sign in
Do you want to remove this advert? Become a member!
Do you want to remove this advert? Become a member!

Support Us

Become a Member